Arax Advisory Partners’s Apogee Therapeutics APGE Stock Holding History

Arax Advisory Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3K	Buy	+123	New	+$11.1K	﹤0.01%	4084
2026 Q1	–	Sell	-26	Closed	-$1.96K	–	3801
2025 Q4	$1.96K	Sell	26 -58	-69%	-$3.65K	﹤0.01%	3268
2025 Q3	$3.34K	Buy	84 +58	+223%	+$2.21K	﹤0.01%	2982
2025 Q2	$1.13K	Hold	26	–	–	﹤0.01%	2735
2025 Q1	$972	Buy	+26	New	+$1K	﹤0.01%	2313

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Arax Advisory Partners's APGE Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 123 shares worth $16.3K. The stake represents ﹤0.01% of the portfolio and ranks #4084 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in APGE as recently as Q4 2025.

Arax Advisory Partners first reported a position in APGE in Q1 2025 and has held it in 5 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Arax Advisory Partners held 123 shares of Apogee Therapeutics worth $16.3K as of Q2 2026.
Apogee Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4084 holding.
Arax Advisory Partners first reported a position in Apogee Therapeutics in Q1 2025 and has held it in 5 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.